回购方案细节：价格9.29元/股，资金来源为自有资金 登录新浪财经APP 搜索【信披】查看更多考评等级 厦门力鼎光电股份有限公司（以下简称"力鼎光电"）近日公告，因部分激励对象不再符合激励条件，公 司将回购注销其持有的6.30万股限制性股票，回购价格为9.29元/股，涉及资金约58.53万元。福建至理 律师事务所已就该事项出具法律意见书，认为本次回购注销程序合规，符合相关法规及公司激励计划安 排。 回购注销原因：6名激励对象不再符合条件 根据公告，本次回购注销源于6名原激励对象因离职或违纪，已不再符合《厦门力鼎光电股份有限公司 2025年限制性股票激励计划》（以下简称《激励计划》）的激励条件。 《激励计划》明确规定，激励对象主动辞职的，其已获授但尚未解除限售的限制性股票不得解除限售， 由公司以授予价格回购注销；激励对象在职期间发生违反工作纪律等不适当行为的，相关限制性股票同 样由公司按授予价格回购注销。基于上述规定及公司与激励对象签署的授予协议，董事会决定对该6名 对象持有的6.30万股限制性股票进行回购注销。 公告显示，本次回购的股份为公司2025年限制性股票激励计划首次授予的限制性股票，回购数量共计 6. ...

Group 1 - The company will hold a shareholders' meeting to review the repurchase and cancellation of part of the restricted stock and the expected related party transactions for 2026, with the repurchase involving 261,500 shares and the total expected related party transaction amount being 236.5 million yuan [1] - The company has released a performance forecast on January 30, 2026, estimating the net profit attributable to shareholders for 2025 to be between 247 million and 263 million yuan, representing a year-on-year growth of 2.57% to 9.21% [2] - The first unlock condition of the company's restricted stock incentive plan has been achieved, allowing 285 incentive targets to unlock 2.3565 million shares, which accounts for 0.58% of the company's total share capital [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 2026年2月11日，兖矿能源集团股份有限公司（股票代码：600188，简称"兖矿能源"）发布公告称，公 司当日召开的第九届董事会第二十一次会议审议通过了《关于回购注销部分激励对象限制性股票的议 案》，同意根据2021年A股限制性股票激励计划，对18名激励对象已获授但尚未解除限售的62.8524万股 限制性股票进行回购注销。因本次回购注销将导致公司注册资本减少，公司已依法通知相关债权人，债 权人可在公告发布之日起45日内申报债权。 董事会决议与回购注销详情 兖矿能源董事会在公告中强调，公司及全体董事保证公告内容真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并对内容的真实性、准确性和完整性承担法律责任。本次回购注销事项的后续进 展，公司将按照相关规定及时履行信息披露义务。 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，不代表新浪财经观 点，任何在本文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑 问，请联系biz@staff.sina.com.cn。 点击查看公告原文>> 责任编辑：小浪快报 ...

Group 1 - The core viewpoint of the article is that Gree Electric Appliances (000651) is considering a share buyback and cancellation plan based on market conditions, operational status, and financial planning [1] - The company emphasizes that any related arrangements will be strictly disclosed in accordance with legal and regulatory requirements [1]

Core Viewpoint - The company announced a plan to repurchase and cancel a portion of restricted stock due to not meeting the 2024 performance assessment targets and the departure of one incentive recipient [1] Group 1: Repurchase Details - The board and supervisory board approved the repurchase of 175,920 shares from 26 incentive recipients at a price of 22.60 yuan per share, along with 16,800 shares from the departed employee, totaling 192,720 shares [1] - The company has opened a dedicated repurchase account and applied for the transfer of shares, with the repurchase and cancellation expected to be completed by January 15, 2026 [1] - Subsequent procedures will include capital reduction and share cancellation registration [1]

Core Viewpoint - In 2025, the pharmaceutical sector in the A-share market is actively engaging in stock buybacks, with many companies opting to destroy the repurchased shares, contrasting with the more subdued actions in the liquor sector [1][10]. Group 1: Buyback Activities - A total of 38 leading pharmaceutical companies participated in stock buybacks, with 6 companies spending over 500 million yuan, and the largest spending 1 billion yuan [1][3]. - WuXi AppTec, a major player in the pharmaceutical outsourcing industry, announced a buyback plan of 1 billion yuan, completing 497 million yuan by April 2025 [2][5]. - Hengrui Medicine, a leader in innovative drugs, announced a buyback plan of 2 billion yuan, having already repurchased 535 million yuan worth of shares by August 2025 [3][6]. - Other notable companies include Jingxin Pharmaceutical, which planned to spend 700 million yuan and has already spent 609 million yuan, and several others like New Harmony, Jiuzan Medical, and Nengte Technology, each spending over 500 million yuan [3][9]. Group 2: Purpose and Impact of Buybacks - The primary purpose of these buybacks is to cancel the repurchased shares, effectively reducing the total share capital and increasing the value of remaining shares for shareholders [4][10]. - This strategy is viewed as a strong signal of management's confidence in the company's future, especially during periods of low market sentiment [5][10]. - The buyback actions are seen as a more tangible commitment to shareholder value compared to merely announcing intentions to stabilize stock prices [4][10]. Group 3: Financial Health and Market Position - The companies engaging in these buybacks, such as WuXi AppTec and Hengrui Medicine, possess strong market positions and cash flows, allowing them to undertake such financial maneuvers [6][10]. - The buyback trend is not as prevalent in the liquor sector, indicating a potential difference in financial strategies and market confidence between the two industries [6][10]. - The buyback prices set by companies reflect a calculated approach, ensuring that they are responsible with shareholder funds [8][10].

Group 1 - The company announced the resignation of its Chief Auditor, Yang Haifeng, effective immediately upon delivery of his resignation letter to the board on December 25, 2025, due to work adjustments [1][2] - Yang Haifeng held 114,400 shares of the company, representing 0.00049% of the total share capital, and will continue to manage his shares according to relevant laws and regulations after his departure [2] - The board expressed gratitude for Yang Haifeng's contributions during his tenure [3] Group 2 - The company adjusted its cash dividend total for the 2025 semi-annual profit distribution, maintaining a cash dividend of RMB 0.5 per 10 shares (including tax), while the total cash dividend amount was revised from RMB 1,164,068,263.10 to RMB 1,163,998,025.20 [5][8] - The adjustment was due to the cancellation of 1,404,758 A-shares of restricted stock, which reduced the total share capital from 23,281,365,262 shares to 23,279,960,504 shares [5][7] - The company plans to maintain the per-share distribution amount while adjusting the total distribution amount based on the new total share capital [8]

Key Points - The company, Beijing Jingwei Hirain Technologies Co., Ltd., held its first extraordinary general meeting of shareholders on December 24, 2025, where several important resolutions were passed, including the repurchase and cancellation of part of the restricted stock incentive plan, the cancellation of the supervisory board, and the use of reserves to cover losses [1][3] - The company plans to repurchase and cancel a total of 18,080 shares of restricted stock due to the departure of 23 incentive targets and 3 targets not meeting performance assessments, resulting in a reduction of total shares from 119,959,040 to 119,940,960 and a decrease in registered capital from 119,958,040 yuan to 119,940,960 yuan [2][3] - On December 24, 2025, the stock closed at 113.76 yuan, up 2.16%, with a turnover rate of 3.34%, a trading volume of 37,300 lots, and a transaction amount of 430 million yuan [1]

Core Viewpoint - The company believes its stock price is undervalued and influenced by market preferences and industry conditions [1] Group 1: Stock Performance and Buyback - The company plans to repurchase and cancel shares worth approximately 8.87 billion yuan by 2025, with the controlling shareholder increasing stock purchases by about 6.23 billion yuan [1] Group 2: Dividend Policy - The company has maintained a consistent cash dividend policy for 16 consecutive years since its listing, with annual increases in per-share dividends, ensuring continuity, stability, and predictability in cash dividends [1] - According to China's personal income tax law, individual investors holding shares of domestic listed companies for over one year are exempt from personal income tax on dividend income [1]

Group 1 - The company is a leading player in the ophthalmology service sector with a market capitalization of over 100 billion [1] - There is a call from investors for the company to adopt a proactive approach similar to other successful companies by increasing share buybacks and management stock purchases to boost investor confidence [1] - The company’s secretary indicated that any future plans for buybacks or management purchases will be disclosed in accordance with regulations [1]